

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 91023

Title: Understanding the role of transmembrane 9 superfamily member 1 in bladder

cancer pathogenesis

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 01206150 Position: Editorial Board Academic degree: MD, PhD

Professional title: Chief Doctor, Research Scientist

Reviewer's Country/Territory: China

Author's Country/Territory: India

Manuscript submission date: 2023-12-20

Reviewer chosen by: AI Technique

Reviewer accepted review: 2024-01-25 02:45

Reviewer performed review: 2024-01-25 03:18

Review time: 1 Hour

	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C:
Scientific quality	Good
	[ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [ Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair
this manuscript	[ ] Grade D: No creativity or innovation



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: office@baishideng.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [ ] Anonymous [ Y] Onymous  Conflicts-of-Interest: [ ] Yes [ Y] No

## SPECIFIC COMMENTS TO AUTHORS

This editorial is well written. And the following sentences need to be polished. 1. For instance, point mutation of FGFR3 gene while seen in 60-70 % of NMIBC is only found in 5-10% of MIBC Recommended revision: For instance, while point mutation of the FGFR3 gene is observed in 60-70% of NMIBC cases, it is only detected in 5-10% of MIBC cases. 2. Upregulation of EGFR is seen in 20% of NMIBC but in up to 50% of MIBC Recommended revision: Recommended revision: The upregulation of EGFR is observed in 20% of NMIBC cases, but it can be seen in up to 50% of MIBC cases. 3.for reference 2. F B, J F, I S, RL S, LA T, A J. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018. 68(6):394–424. The authors should be: Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 4. "pathogensis" should be "pathogenesis".